Mr. Hirokazu Kobayashi
Managing Director

At first, on behalf of Daiichi Sankyo (Thailand) Ltd., I would like to express our sincere appreciation for your continued support and cooperation.

Daiichi Sankyo is a global pharmaceutical company with its corporate origins in Japan, and with a legacy of more than 100 years of scientific expertise, the company has developed various innovative pharmaceutical products including, but not limited to, Tranexamic acid, Loxoprofen, Pravastatin, Olmesartan Medoxomil, Ofloxacin, Levofloxacin, Sitafloxacin, Prasugrel, Edoxaban, and Mirogabalin. In addition, under ESG management based on the current mid-term business plan, Daiichi Sankyo is striving to achieve our 2025 Goal of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology” as well as steadily making progress toward the realization of our 2030 Vision to further transform the company into an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

Daiichi Sankyo has established its ADC technology for oncology products and has variety of compounds under development in its pipeline across various oncology areas. One of the innovative, ADC products is DS-8201, which is marketed under the brand name of Enhertu in the US, Europe, Japan and other regions, where it is approved to treat to patients suffering from breast cancer, lung cancer and gastric cancer.

In Thailand, Daiichi Sankyo (Thailand) Ltd. has nearly a 30-year business history, focusing mainly on the cardiovascular, infectious disease, and pain fields. Looking ahead to the future, we are hoping that we can be of help to patients and healthcare professionals through the provision of medical information and the distribution of oncology products, including DS-8201, which will be marketed in collaboration with AstraZeneca (Thailand) Ltd.

The Purpose of Daiichi Sankyo (Thailand) Ltd. is to “Contribute to the sustainable development of healthcare and society in Thailand and enrich patients’ lives”, and our company’s Mission is “Providing innovative pharmaceutical products and medical information to stakeholders in cardiovascular, infectious, pain as well as oncology fields.” Moreover, within our own 2030 vision, we aim to be a company that is “Professional, trusted healthcare company contributing sustainable improved quality of life in Thailand”.